WANG-HUEI SHENGSUI-YUAN CHANGLin, Pin-HungPin-HungLinMING-JU HSIEHHAO-HSIANG CHANGCheng, Chien-YuChien-YuChengHUNG-CHIH YANGPan, Ching-FuChing-FuPanIeong, Si-ManSi-ManIeongTAI-LING CHAOChen, Jang-PinJang-PinChenCheng, Shu-HsingShu-HsingChengSHAN-CHWEN CHANG2022-05-122022-05-122022-040929-6646https://scholars.lib.ntu.edu.tw/handle/123456789/610521Efficacy and safety data of heterologous prime-boost vaccination against SARS-CoV-2 remains limited.enAdenovirus-vector vaccine; Coronavirus disease 2019 (COVID-19); Immune response; Messenger RNA vaccine; Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)[SDGs]SDG3Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccinationjournal article10.1016/j.jfma.2022.02.020353058952-s2.0-85126553951https://scholars.lib.ntu.edu.tw/handle/123456789/604311